Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: Correlation with molecular modeling interaction studies

Nuclear Medicine and Biology

Volumn 29, Issue 3, 2002, Pages 329-338

  Neves, M ^a   Gano, L ^a   Pereira, N ^a   Costa, M C ^b   Costa, M R ^b   Chandia, M ^c   Rosado, M ^d   Fausto, R ^d  

^a INSTITUTO TECNOLÓGICO E NUCLEAR   (Portugal)

^b INETI   (Portugal)

^c Chilean Commission for Nuclear Energy   (Chile)

^d UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Bisphosphonates; Hydroxyapatite binding; Molecular modeling; Therapeutic radiopharmaceuticals

Indexed keywords

ALENDRONIC ACID SM 153; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; HYDROXYAPATITE; IBANDRONIC ACID; NERIDRONIC ACID; NERIDRONIC ACID SM 153; OLPADRONIC ACID; PAMIDRONIC ACID SM 153; RADIOPHARMACEUTICAL AGENT; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATOM; BONE MINERAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ADSORPTION; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; GEOMETRY; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MOLECULAR MODEL; MOUSE; NONHUMAN; OSTEOLYSIS; PREDICTION; RADIOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ALENDRONATE; ANIMALS; BONE AND BONES; DIPHOSPHONATES; DURAPATITE; ENERGY TRANSFER; FEMALE; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RADIOCHEMISTRY; RADIOISOTOPES; RADIOPHARMACEUTICALS; SAMARIUM; TISSUE DISTRIBUTION;

EID: 0036203472     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(01)00305-5     Document Type: Article

References (33)

1. Structure of disodium dihydrogen 1-hydroxyethylenediphosphonate tetrahydrated: A bone growth regulator
2. Interactions at the organic/inorganic interface: Binding motifs for phosphonates at the surface of barite crystals
3. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases
4. Molecular mechanics
5. Molecular modelling of the mechanism of action of phosphonate retarders on hydrating cements
6. Technetium chemistry and technetium radiopharmaceuticals
7. Bisphosphonates: Mechanism of action
8. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo
9. Comparative evaluation of three diphosphonates: In vitro adsorption (C-14 labeled) and in vivo osteogenic uptake (Tc-99m complexed)
10. Bisphosphonates induce breast cancer cell death in vitro
11. Antitumor potential of bisphosphonates
12. 99mTc(Sn) diphosphonate complexes on tri-calciumphosphate: The influence of preparation conditions, ligand type, incubation media and adsorption conditions. The reversibility of the adsorption
13. Derivation of class 2. Derivation and characterization of a class II force field, CFF93, for the alkyl functional group and alkane molecules
14. 2O. Implications for the chemistry of technetium-99m-diphosphonate skeletal imaging agents
15. Crystal structure of hydroxyapatite
16. 186Re-HEDP as bone therapeutic radiopharmaceuticals
17. (4-amino-1-hydroxybutylidene) bisphosphonic acid sodium salt, MK-217 (alendronate sodium). An improved procedure for the preparation of 1-hydroxy-1,1-bisphosphonic acids
18. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
19. 99mTc skeletal imaging agents
20. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones
21. Use of radionuclides for the palliation of bone metastases
22. Anion-exchange high-performance liquid chromatography of technetium-labelled phosphonoacetic acid skeletal imaging agents preparations
23. Preclinical studies with zoledronic acid and other bisphosphonates on the bone microenvironment
24. Calorimetric and laser induced fluorescence investigation of the complexation geometry of selected europium gem-diphosphonate complexes in acidic solutions
25. Lanthanide complexes with 1-hydroxyethane-1.1-diphosphonic acid: Solvent organization and coordination geometry in crystalline and amorphous solids
26. Molecular mechanism of action of bisphosphonates
27. Bisphosphonates: From the laboratory to the clinic and back again
28. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
29. Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity
30. Monosodium 4-amino-1-hydroxy-1,1-butane-diyldiphosphonate trihydrate (alendronate)
31. Metal-ion specification in blood plasma incorporating the bisphosphonate, 1-hydroxy-4-aminopropilydenediphosphonate (APD), in therapeutic radiopharmaceuticals